Related Experiment Videos
Recombinant activated factor VII and the anaesthetist.
I J Welsby1, D M Monroe, J H Lawson
1Department of Anaesthesiology, Duke University Medical Center, Durham, NC 27710, USA. welsb001@mc.duke.edu
Anaesthesia
|November 18, 2005
Summary
Recombinant activated factor VII (rFVIIa) is safe and effective for treating bleeding in hemophiliacs and Glanzmann
Area of Science:
- Hematology
- Pharmacology
Background:
- Recombinant activated factor VII (rFVIIa) is a procoagulant agent.
- It facilitates thrombin generation on activated platelets and monocytes.
- This mechanism offers potential for hemostasis in various coagulopathic states.
Purpose of the Study:
- To evaluate the safety and efficacy of rFVIIa.
- To explore its use in hemophiliacs with inhibitors and Glanzmann's thrombasthenia.
- To review off-label applications and identify the need for further research.
Main Methods:
- Literature review focusing on case reports and randomized controlled studies.
- Analysis of rFVIIa's mechanism of action in restoring thrombin generation.
- Assessment of existing evidence for both approved and off-label uses.
Main Results:
- rFVIIa demonstrates safety and efficacy in specific bleeding disorders.
- Successful rescue therapy reported in numerous off-label cases.
- Existing randomized trials are often underpowered for comprehensive safety assessment.
Conclusions:
- rFVIIa is a valuable therapeutic option for specific hemorrhagic conditions.
- Off-label use is increasing, supported by case report literature.
- Further randomized controlled trials are needed to establish safe and appropriate use in broader patient populations.